ArticleProceedings of the National Academy of Sciences of the United States of America2022
FXR mediates ILC-intrinsic responses to intestinal inflammation.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 55 citations in OpenAlex.
- The gut microbiome-bile acid-FXR interplay: a pivotal axis in metabolic and gastrointestinal diseases.Gut microbes · 2026Review
- Pleiotropic roles of microbial bile acid metabolism in intestinal health and diseases.Cell host & microbe · 2026Review
- Obeticholic acid attenuates complete freund's adjuvant-induced arthritis in rats through FXR-mediated modulation of TGF-β/TAK1/MKK3/p38 MAPK signaling, inflammation, and oxidative stress.Inflammopharmacology · 2026Article
- Oral probiotic delivery-based therapeutic strategies for inflammatory bowel disease.Asian journal of pharmaceutical sciences · 2026Review
- Intestinal FXR deficiency uncouples steatosis protection from liver inflammation and fibrosis in MASH-diet fed mice.Scientific reports · 2026Article
- FXR overexpression promotes liver regeneration through inducing FGF2 activation in APAP-induced acute liver injury.Hepatology international · 2026Article
- The gut-liver axis modulates intestinal immune homeostasis.Mucosal immunology · 2026Review
- Article
- Dysregulated immunometabolism in gut inflammation.Acta biochimica et biophysica Sinica · 2026Review
- Inflammatory bowel diseases: pathological mechanisms and therapeutic perspectives.Molecular biomedicine · 2026Review
- Microbial transformation of secondary bile acids: roles in gut ecology and autoimmune diseases.Frontiers in immunology · 2026Review
- Farnesol, the farnesol pathway, and the immune-gut-brain axis.Frontiers in pharmacology · 2026Review
- Pleiotropic immunoregulation by bile acids in pathophysiology.Frontiers in immunology · 2026Review
- Predictive model for ulcerative colitis therapeutic response using clinical indicators and peripheral blood T-cell subsets.Frontiers in immunology · 2026Article
- Targeting the gut-lung axis in COPD: from microbial metabolites to fecal microbiota transplantation.Frontiers in microbiology · 2026Review
- Duodenal mucosal RNA-Seq identifies coordinated bile acid-axis transcriptional alterations in food-responsive enteropathy in dogs.Frontiers in veterinary science · 2026Article
- The shifting balance: innate lymphoid cell plasticity in chronic gut diseases.Frontiers in immunology · 2026Review
- The Microbial Bile Acid Metabolite 3-Oxo-LCA Inhibits Colorectal Cancer Progression.Cancer research · 2025Article
- Faecalibacterium prausnitzii Ameliorates DSS-Induced Colitis via Modulating Bile Acid Metabolism and Regulating FXR Signaling.Digestive diseases and sciences · 2025Article
- Advances of exosome regulating‑FXR to repair inflammatory bowel disease (Review).International journal of molecular medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 2 countries.
Funding
Abstract
The pleiotropic actions of the Farnesoid X Receptor (FXR) are required for gut health, and reciprocally, reduced intestinal FXR signaling is seen in inflammatory bowel diseases (IBDs). Here, we show that activation of FXR selectively in the intestine is protective in inflammation-driven models of IBD. Prophylactic activation of FXR restored homeostatic levels of pro-inflammatory cytokines, most notably IL17. Importantly, these changes were attributed to FXR regulation of innate lymphoid cells (ILCs), with both the inflammation-driven increases in ILCs, and ILC3s in particular, and the induction of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.